We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.

Delisted

GNCA was delisted on the 2nd of June, 2022.

45 hedge funds and large institutions have $57.4M invested in Genocea Biosciences, Inc. in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,563% more call options, than puts

Call options by funds: $6.02M | Put options by funds: $362K

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

61% more capital invested

Capital invested by funds: $35.6M → $57.4M (+$21.7M)

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

10% more funds holding

Funds holding: 4145 (+4)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
0.98%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
19
Increased
15
Reduced
6
Closed
14
Calls
$6.02M
Puts
$362K
Net Calls
+$5.66M
Net Calls Change
+$4.77M

GNCA Hedge Fund Activity: Q2 2019 in Review

45 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2019, worth a combined $57.4M — up 61% from $35.6M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new GNCA positions and 14 closed out — a net gain of 5 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was NEA Management Company, adding an estimated $14.9M. The largest seller was Vivo Capital, cutting an estimated $1.83M.

  • 45 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2019, up from 41 in Q1 2019.
  • Funds reported $57.4M of Genocea Biosciences, Inc. stock for Q2 2019, up 61% quarter-over-quarter.
  • 19 funds opened new Genocea Biosciences, Inc. positions in Q2 2019 and 14 closed out, a net change of +5 holders.
  • The largest Genocea Biosciences, Inc. buyer in Q2 2019 was NEA Management Company, an estimated $14.9M added.
  • The largest Genocea Biosciences, Inc. seller in Q2 2019 was Vivo Capital, an estimated $1.83M sold.

Based on aggregated 13F filings for Q2 2019.